Cara Therapeutics | CARA - Sales Revenues

Stock Price
3.93
Daily Change
-0.09 -2.24%
Monthly
2.88%
Yearly
-73.37%
Q1 Forecast
3.87

Cara Therapeutics reported $2.57M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Alterity Therapeutics Limited AUD 11.38K 10.23K Dec/2022
Assertio Holdings USD 29.2M 1.92M Sep/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Chugai Pharma JPY 346.3B 13.12B Dec/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 1.89M 631K Sep/2025
CSL USD 8.33B 4.79B Dec/2025
Grifols EUR 2.34B 159.69M Mar/2026
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
J&J USD 24.6B 610M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
RedHill Biopharma USD 1.29M 722K Jun/2024
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024